CEO of pSivida to discuss new technologies in retinal drug delivery at the San Diego Ophthalmic summit

NewsGuard 100/100 Score
Sep 19 2009

pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr. Paul Ashton, CEO, will lead a discussion on New Technologies in Retinal Drug Delivery at the 5th Annual Ophthalmic Drug Development and Delivery Summit to be held September 21-22, 2009 in San Diego.

Dr. Ashton will describe the anatomical and technical difficulties of drug delivery to the retina; the advantages and disadvantages of earlier approaches to overcome these obstacles; current attempts to achieve effective dosing to the retina and provide an outlook on future developments in retinal delivery.

More information on the Summit can be found at its website: http://www.pharmedassociates.com.

www.psivida.com

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Neural circuits respond to rapid dopamine surges
Nanotechnology could enhance traditional Chinese medicine delivery, promising improved clinical outcomes
Octopus-inspired suction patch revolutionizes drug delivery, promising an injection-free future
3D-printed vaginal ovules offer promising treatment for endometriosis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Nanotechnology's triple threat: Advancing precision cancer treatment